# Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

> **NCT06571422** · PHASE1 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 93 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** WJ47156
- **DRUG:** JS001+Bevacizumab
- **DRUG:** JS207

## Key facts

- **NCT ID:** NCT06571422
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2026-05-15
- **Final completion:** 2027-04-30
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571422, "Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06571422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*